HARVARD BIOSCIENCE INC
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
HBIO$9.26+1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders' Equity
| HARVARD BIOSCIENCE, INC. | ||||||
|---|---|---|---|---|---|---|
| CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY | ||||||
| (Unaudied, in thousands) | ||||||
| Accumulated | ||||||
| Three Months Ended · Number · Additional · Other · Total | ||||||
| March 31, 2024 | of Shares | Common | Paid-in | Accumulated | Comprehensive | Stockholders’ |
| Issued | Stock | Capital | Deficit | Loss | Equity | |
| Balance at December 31, 2023 | 43,395 | $434 | $232,435 | $(145,605) | $(14,190) | $73,074 |
| Stock option exercises | 4 | - | 15 | - | - | 15 |
| Vesting of restricted stock units | 34 | - | - | - | - | - |
| Shares withheld for taxes | (12) | - | (47) | - | - | (47) |
| Stock-based compensation expense | - | - | 1,048 | - | - | 1,048 |
| Net loss | - | - | - | (4,694) | - | (4,694) |
| Other comprehensive loss | - | - | - | - | (584) | (584) |
| Balance at March 31, 2024 | 43,421 | $434 | $233,451 | $(150,299) | $(14,774) | $68,812 |
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Three Months Ended · Number · Additional · Other · Total | ||||||
| March 31, 2023 | of Shares | Common | Paid-in | Accumulated | Comprehensive | Stockholders’ |
| Issued | Stock | Capital | Deficit | Loss | Equity | |
| Balance at December 31, 2022 | 42,082 | $454 | $229,008 | $(142,190) | $(15,052) | $72,220 |
| Stock option exercises | 39 | 1 | 103 | - | - | 104 |
| Vesting of restricted stock units | 125 | - | - | - | - | - |
| Shares withheld for taxes | (56) | - | (156) | - | - | (156) |
| Stock-based compensation expense | - | - | 1,153 | - | - | 1,153 |
| Net income | - | - | - | 622 | - | 622 |
| Other comprehensive income | - | - | - | - | 397 | 397 |
| Balance at March 31, 2023 | 42,190 | $455 | $230,108 | $(141,568) | $(14,655) | $74,340 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.